Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

Journal of Rheumatology

Volumn 36, Issue 4, 2009, Pages 801-808

  Rudwaleit, Martin ^a   Claudepierre, Pascal ^b,c   Wordsworth, Paul ^d   Cortina, Eduardo Loza ^e   Sieper, Joachim ^a   Kron, Martina ^f   Carcereri De Prati, Roberto ^f   Kupper, Hartmut ^f   Kary, Sonja ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^e Universidad Pública de Navarra   (Spain)

^f ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Adalimumab; Ankylosing spondylitis; Extraaxial arthritis; Predictor; Tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; ALKYLATING AGENT; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; BUPRENORPHINE; C REACTIVE PROTEIN; CHLORAMBUCIL; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FENTANYL; GLUCOCORTICOID; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPTIC NEURITIS; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 66149125235     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081048     Document Type: Article

References (31)

1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. Arthritis Rheum 2005;52:4048-9; author reply 4049-50. Comment on: Arthritis Rheum 1998;41:58-67.
3. Davis JC Jr. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 2004;34:668-77.
4. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;56:442-52.
5. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005:CD004800.
6. van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
7. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
8. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
9. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
10. van der Heijde D, Dijkmans B, Geusens P, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
11. van der Heijde D, Kivitz A, Schiff MH, et al; Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2136-46.
12. Calin A, Dijkmans BAC, Emery P, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
13. Davis JC Jr, van der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
14. Davis JC, van der Heijde D, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
15. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
16. Maksymowych WP, Rahman P, Keystone E, et al. Efficacy of adalimumab in active ankylosing spondylitis (AS): Results of the Canadian AS Study [abstract]. Arthritis Rheum 2005;52 Suppl:S217.
17. Lambert RGW, Salonen D, Rahman P, et al; M03-606 Study Group. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS). Arthritis Rheum 2007;56:4005-14.
18. Braun J, Pham T, Sieper J, van der Linden S, Dougados M, van der Heijde D. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
19. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
20. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment. Ann Rheum Dis 2004;63:1438-44.
21. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
24. Braun J, van der Heijde D, Dougados M, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis 2002;61 Suppl III:19-23.
25. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
26. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
27. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
28. Pham T, Landewé R, van der Linden S, et al. An international study on starting tumor necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006;65:1620-5.
29. van der Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
30. Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. Definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann Rheum Dis 2006;65:1518-20.
31. Davis JC, van der Heijde D, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.